Precision BioSciences, an early stage cancer biotech developing gene-edited Car T Cell therapies, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
The Durham, NC-based company was founded in 2006 and booked $11 million in collaboration revenue for the 12 months ended December 31, 2018. It plans to list on the Nasdaq under the symbol DTIL. Precision BioSciences filed confidentially on October 19, 2018. J.P. Morgan, Goldman Sachs, Jefferies and Barclays are the joint bookrunners on the deal. No pricing terms were disclosed.
